A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-06. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Norman language === Main articles: Norman language and Cauchois dialect. The legacy of the Norman language is present in the language used by the people of Le Havre, part of which is identified as speaking cauchois. Among the Norman words most used in Le Havre there are: boujou (hello, goodbye), clenche (door handle), morveux (veuse) (child), and bezot (te) (last born).
If the TP53 gene is damaged, its ability to suppress tumors is severely compromised. Individuals who inherit only one functional copy of TP53 are predisposed to developing tumors in early adulthood, a condition known as Li–Fraumeni syndrome. The TP53 gene can also be altered by mutagens—such as chemicals, radiation, or certain viruses—thereby increasing the likelihood of uncontrolled cell division. More than 50 percent of human tumors harbor a mutation or deletion of the TP53 gene. Loss of p53 function leads to genomic instability, frequently resulting in an aneuploidy phenotype. Certain pathogens can also disrupt p53 activity. For example, human papillomavirus (HPV) produces the viral protein E6, which binds to and inactivates p53. In conjunction with the HPV protein E7, which inactivates the cell cycle regulator pRb, this promotes repeated cell division, clinically presenting as warts. High-risk HPV types, particularly types 16 and 18, can drive the progression from benign warts to low- or high-grade cervical dysplasia, reversible precancerous lesions. Persistent cervical infection can lead to irreversible changes, including carcinoma in situ and invasive cervical cancer. These outcomes are primarily driven by viral integration into the host genome and the continued expression of the E6 and E7 oncoproteins.
== Contraindications == It is contraindicated if there has been a past history of angioedema; heart conduction disorders (e.g. sick sinus syndrome, second- or third-degree heart block); bradycardia; severe heart failure or coronary artery disease. Also: Raynaud's syndrome, intermittent claudication, epilepsy, depression, Parkinson's disease, glaucoma. Use in pregnancy is discouraged. Moxonidine passes into breast milk. Moxonidine should be avoided in patients with moderate to severe renal impairment. Abrupt discontinuation of the drug should also be avoided. If concomitant treatment with a beta blocker has to be stopped, the beta blocker should be discontinued first, then moxonidine after a few days. Alcohol may potentiate the hypotensive effects of Moxonidine. Excess mortality has been seen in patients with symptomatic heart failure in the MOXCON study. However, the MOXCON trial utilised a very high dose of 3.0 mg daily which is well above the normal dose of 0.2–0.6 mg daily.
Sources: en.wikipedia.org
== Personal history == Huggins was born in 1897 to Amos Williamson Huggins and Mary Abigail Hackley. He had at least two sisters, Dorothea Harriet Huggins (born September 22, 1894) and Mary Abigail Huggins (born October 2, 1904). He earned his Ph.D. in 1922 under Charles Walter Porter (known as Walter Porter) in the Chemistry Laboratory of the University of California, Berkeley. In 1941 he was elected a Fellow of the American Physical Society. He was employed as a chemist by Eastman Kodak Research Laboratories.
Nando's (; Afrikaans: [ˈnandœs]) is a South African multinational fast casual restaurant chain that specialises in Portuguese flame-grilled, peri-peri style chicken. The name is derived from a nickname for the male given name Fernando, in reference to one of the company's founders. Founded in Johannesburg in 1987, Nando's operates over 1,200 outlets in 30 countries. Their logo depicts the Rooster of Barcelos, one of Portugal's most common symbols. The company was wholly owned by Dick Enthoven until his death in 2022, and is now owned by his family.
==== Danish ==== Danish Brotherhood in America Danish Sisterhood - Founded December 15, 1883, in Negaunee, Michigan, by Mrs. Christine Hemmingsen. A supreme lodge was formed in 1887, and all the officers were women by 1910. Membership was open to women of Danish descent or married to a man of Danish descent. Admission is by black ball, with one blackball enough to disqualify; there is always a second ballot; if there is another blackball a selected secret committee is appointed to determine the cause. Had a secret ritual, and no uninitiated person may attend secret meetings of the lodge. Locals are called "lodges"; regional groups are called "Districts". National convention meets quadrennially. Supreme Lodge headquarters is in Chicago. Provides funeral benefits of up to $1,000, no more than two beneficiaries can be designated, and in special circumstances, other benefits can be applied for. Membership in 1922, 8,000, 1934, 7,000, and 1979, 4,500.
Full-thickness skin grafts are the effective wound-management technique for defects with a well-vascularized, soft-tissue bed covering the nasal skeleton. The patient's ear is the preferred skin-graft donor site from which to harvests grafts of pre-auricular skin and grafts of post-auricular skin, usually with an additional, small amount of adipose tissue to fill the wound cavity. Yet, nasal correction with a skin graft harvested from the patient's neck is not recommended, because that skin is low-density pilosebaceous tissue with very few follicles and sebaceous glands, thus is unlike the oily skin of the nose. The technical advantages of nasal-defect correction with a skin graft are a brief surgery time, a simple rhinoplastic technique, and a low incidence of tissue morbidity. The most effective corrections are with a shallow wound with sufficient, supporting soft-tissue that will prevent the occurrence of a conspicuous depression. Nonetheless, two disadvantages of skin-graft correction are mismatched skin color and skin texture, which might result in a correction with a patch-work appearance; a third disadvantage is the natural histologic tendency for such skin grafts to contract, which might distort the shape of the corrected nose.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.